ArticleStem cell research & therapy2025
Stem cells harvested from different sources ameliorate liver fibrosis: comparative study.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Treatment of Chronic Liver Fibrosis: Adipose and Bone Marrow Mesenchymal Stem Cells.International journal of molecular sciences · 2026Article
- iMSC-secreted factors preserve renal capillary networks and ameliorate fibrosis by interrupting the macrophage STING/CD8Stem cell research & therapy · 2026Article
- A machine learning model for 90-day mortality prediction in hepatitis B virus-related acute-on-chronic liver failure: the pivotal role of CALLY index.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatic fibrosis is a serious illness that can lead to death. Until recently, there has been no effective medication to protect the liver and heal fibrosis. When thioacetamide (TAA)-induced hepatotoxicity occurred, we aimed to determine the hepatoprotective effectiveness of adipose, bone marrow, and liver-derived mesenchymal stem cells. Fifty male albino Wistar rats were used throughout the study and divided into 5 groups. Each group had 10 rats divided into 2 cages, 5 rats per cage. Forty male albino Wistar rats were injected intraperitoneally with 100 mg/kg of thioacetamide 2 times a week for 9 weeks. After 5 weeks of induction of liver fibrosis, forty rats were divided into four groups. One group was considered the TAA group and didn't receive any treatment, and the other three groups were inoculated with a single dose of 3 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.